Cytosorbents Corporation CTSO
$5.75
$0.020.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.17% | 1.57% | 0.91% | 10.12% | 8.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.17% | 1.57% | 0.91% | 10.12% | 8.76% |
| Cost of Revenue | -7.81% | 8.49% | -16.09% | -16.03% | 19.84% |
| Gross Profit | 3.45% | -1.24% | 8.78% | 26.83% | 4.78% |
| SG&A Expenses | -13.12% | -3.36% | 20.94% | 3.06% | 7.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.30% | -5.60% | 3.31% | -8.96% | 6.61% |
| Operating Income | 34.50% | 21.71% | -9.25% | 43.72% | -1.26% |
| Income Before Tax | -326.86% | -246.79% | 40.62% | -29.01% | 145.34% |
| Income Tax Expenses | -- | -- | 100.00% | -- | -- |
| Earnings from Continuing Operations | -326.86% | -246.79% | 27.36% | -14.52% | 145.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -326.86% | -246.79% | 27.36% | -14.52% | 145.34% |
| EBIT | 34.50% | 21.71% | -9.25% | 43.72% | -1.26% |
| EBITDA | 37.12% | 23.44% | -11.24% | 47.14% | -1.32% |
| EPS Basic | -326.13% | -235.66% | 36.73% | 0.59% | 139.32% |
| Normalized Basic EPS | -312.32% | -235.71% | 56.59% | -9.80% | 139.27% |
| EPS Diluted | -334.42% | -235.66% | 36.73% | 0.59% | 137.50% |
| Normalized Diluted EPS | -327.79% | -235.71% | 56.59% | -9.80% | 136.64% |
| Average Basic Shares Outstanding | 0.32% | 3.30% | 14.78% | 15.24% | 15.29% |
| Average Diluted Shares Outstanding | -6.49% | 3.30% | 14.78% | 15.24% | 23.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |